Biogen Slides As FDA Calls For Investigation Into Approval Of Controversial Alzheimer's Drug
July 09, 2021 at 15:48 PM EDT
Shares of Biogen sank to their lowest levels of the session, weighing on the broader biotech sector.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|